To the full analysis
Buyback calculator for Regeneron Pharmaceuticals
Regeneron Pharmaceuticals stock: key metrics
REGNRegeneron Pharmaceuticals had an operating margin of 24.9% and a return on invested capital (ROIC) of 12.7% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 64.2% | −169.1% | −161.3% |
| 2007 | 0.0% | −91.5% | −84.5% |
| 2008 | 94.9% | −37.7% | −34.7% |
| 2009 | 95.8% | −19.5% | −17.9% |
| 2010 | 95.3% | −21.2% | −22.8% |
| 2011 | 92.1% | −46.0% | −49.7% |
| 2012 | 91.2% | 33.4% | 54.4% |
| 2013 | 90.7% | 35.3% | 20.2% |
| 2014 | 90.9% | 29.2% | 12.3% |
| 2015 | 88.6% | 30.5% | 15.5% |
| 2016 | 91.7% | 27.4% | 18.4% |
| 2017 | 90.8% | 35.4% | 20.4% |
| 2018 | 91.3% | 37.8% | 36.4% |
| 2019 | 85.1% | 33.7% | 32.3% |
| 2020 | 84.0% | 42.1% | 41.3% |
| 2021 | 83.1% | 55.7% | 50.2% |
| 2022 | 86.0% | 44.2% | 35.6% |
| 2023 | 82.9% | 33.2% | 30.1% |
| 2024 | 86.1% | 28.1% | 31.1% |
| 2025 | 85.4% | 24.9% | 31.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −47.2% | −15.7% | −17.5% |
| 2007 | −22.9% | −13.0% | −11.3% |
| 2008 | −19.7% | −9.9% | −12.3% |
| 2009 | −17.1% | −9.5% | −9.2% |
| 2010 | −19.8% | −25.5% | −9.6% |
| 2011 | −45.7% | −38.9% | −16.8% |
| 2012 | 60.2% | 51.5% | 36.1% |
| 2013 | 21.7% | 28.0% | 14.4% |
| 2014 | 13.7% | 21.3% | 9.0% |
| 2015 | 17.4% | 25.6% | 11.3% |
| 2016 | 20.1% | 26.1% | 12.8% |
| 2017 | 19.5% | 25.7% | 13.7% |
| 2018 | 27.9% | 40.1% | 20.8% |
| 2019 | 19.1% | 25.3% | 14.3% |
| 2020 | 31.9% | 35.2% | 20.5% |
| 2021 | 43.0% | 59.8% | 31.7% |
| 2022 | 19.1% | 28.8% | 14.9% |
| 2023 | 15.2% | 23.1% | 12.0% |
| 2024 | 15.0% | 18.0% | 11.7% |
| 2025 | 14.4% | 12.7% | 11.1% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 5 Jun 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.